European Pharmaceutical Pricing & Reimbursement

SMi's 21st annual European Pharmaceutical Pricing & Reimbursement conference, taking place on 5-6 October 2015 in London, will bring together senior industry figures from big pharma, biotech and academia discussing recent updates and highlighting strategies to deal with the latest P&R developments through keynote addresses, case studies and roundtable discussions. International changes in policy will also be highlighted, along with an in-depth focus on biosimilar dugs and the impact that they have had on P&R through nations across Europe.
Benefits of attending:- Evaluate new models for European reimbursement
- Develop understanding of tiered pricing options with case studies from GSK
- Gain further insight into current HTA policies
- Receive invaluable information from field leaders through in-depth case studies
- Learn about changes in UK P&R policy following the UK elections from industry bodies EMIG and the ABPI
Speaker Panel includes:- Leslie Galloway, Chairman, Ethical Medicines Industry Group
- Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
- Janice Haigh, Practice Leader Market Access, Quintiles
- Ken Walsh, Head Emerging Markets Pricing, GSK
- Toros Sahin, Head of Market Access & Health Economics, Sanofi Turkey
- David Watson, Director of Pricing & Reimbursement, ABPI
- Alexander Roediger, Director European Union Affairs, MSD
- Leyla Hannbeck, Head of Pharmacy, National Pharmaceutical Association Ltd
- Eric Low, CEO, Myeloma UK
The conference will also feature an interactive post-conference workshop on: HTA Uncovered, led by Anke Van Engen, Chief Development Officer and Janice Haigh, Practice Leader Market Access, Quintiles, taking place on the 7th October 2015 in London.